Organon & Co. (NYSE:OGN) Shares Acquired by Thompson Siegel & Walmsley LLC

Thompson Siegel & Walmsley LLC increased its stake in shares of Organon & Co. (NYSE:OGN) by 6.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,262,379 shares of the company’s stock after purchasing an additional 136,457 shares during the quarter. Thompson Siegel & Walmsley LLC owned 0.88% of Organon & Co. worth $43,279,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of OGN. Vanguard Group Inc. lifted its holdings in shares of Organon & Co. by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company’s stock valued at $578,849,000 after buying an additional 192,613 shares during the period. O Shaughnessy Asset Management LLC increased its holdings in shares of Organon & Co. by 187.1% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 39,758 shares of the company’s stock valued at $747,000 after purchasing an additional 25,909 shares in the last quarter. UniSuper Management Pty Ltd acquired a new stake in shares of Organon & Co. in the first quarter valued at about $982,000. Shell Asset Management Co. boosted its holdings in Organon & Co. by 180.8% during the first quarter. Shell Asset Management Co. now owns 16,661 shares of the company’s stock worth $313,000 after buying an additional 10,727 shares in the last quarter. Finally, Keeley Teton Advisors LLC grew its position in Organon & Co. by 2.7% during the first quarter. Keeley Teton Advisors LLC now owns 56,014 shares of the company’s stock worth $1,053,000 after buying an additional 1,487 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Organon & Co. Price Performance

OGN stock opened at $14.73 on Thursday. The stock’s 50 day moving average price is $17.82 and its 200 day moving average price is $19.85. The firm has a market cap of $3.79 billion, a P/E ratio of 2.92, a PEG ratio of 0.68 and a beta of 0.84. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $23.10.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The firm’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.78 earnings per share. On average, sell-side analysts expect that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th will be issued a dividend of $0.28 per share. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.61%. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. downgraded Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their price target for the stock from $18.00 to $20.00 in a research note on Friday, September 6th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.